Date: 2011-07-14
Type of information: Grant
Company: Ark Therapeutics (UK)
Investors: European Commission’s Seventh Framework Program (FP7)
Amount: €5.3 million
Funding type: grant
Planned used: The Grant will fund research that combines the technologies of the participants.
Others: Ark Therapeutics has received notice of the award of a €5.3 million EU Framework Programme 7 Grant to a consortium led by Ark including two other SMEs and elements of the Yale-UCL Research Collaborative (Division of Medicine in UCL, and Departments of Cardiology in Yale and Queen Mary College London) and the University of Eastern Finland. The Grant supports the consortium's involvement in a research programme to translate cutting edge biotechnology in the coronary stent area over four years. The Grant is subject to the formal process of contract negotiation with the European Commission which is anticipated to reach conclusion in September. Ark's successful grant application was chosen from more than 40 applications across Europe and received an overall score of 13.5 out of a possible 15 from the EC's independent scientific report on the project's technology.
Therapeutic area: Cardiovascular diseases
